Plasma and prostate phytoestrogen concentrations in prostate cancer patients after oral phytoestogen supplementation

Prostate

Volumn 66, Issue 1, 2006, Pages 82-87

  Rannikko, Antti ^a   Petas, Anssi ^a   Rannikko, Sakari ^a   Adlercreutz, Herman ^b  

^a HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

Author keywords

Daidzein; Fluoroimmunoassay; Genistein; Prostatectomy

Indexed keywords

DAIDZEIN; EQUOL; GENISTEIN; ISOFLAVONE; O NORANGOLENSIN; PHYTOESTROGEN; PLACEBO; PROSTATE SPECIFIC ANTIGEN; TRINOVIN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PREVENTION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; CLOVER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG TISSUE LEVEL; FLUOROIMMUNOASSAY; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; PROSTATECTOMY; RANDOMIZED CONTROLLED TRIAL;

ADMINISTRATION, ORAL; AGED; DIETARY SUPPLEMENTS; GENISTEIN; HUMANS; ISOFLAVONES; MALE; MIDDLE AGED; PHYTOESTROGENS; PHYTOTHERAPY; PLACEBOS; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 29344463843     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.20315     Document Type: Article

References (40)

1. Parkin DM, International Agency for Research on Cancer, International Association of Cancer Registries. Cancer incidence in five continents, Volume VIII. Lyon, France: International Agency for Research on Cancer; 2002.
2. Boyle P, Maisonneuve P, Napalkov P. Geographical and temporal patterns of incidence and mortality from prostate cancer. Urology 1995;46:47-55.
3. Hsing AW, Devesa SS. Trends and patterns of prostate cancer: What do they suggest? Epidemiol Rev 2001;23:3-13.
4. Breslow N, Chan CW, Dhom G, Dhom G, Drury RA, Franks LM, Gellei B, Lee YS, Lundberg S, Sparke B, Sternby NH, Tulinius H. Latent carcinoma of prostate at autopsy in seven areas. The International Agency for Research on Cancer, Lyons, France. Int J Cancer 1977;20:680-688.
5. Nakata S, Takahashi H, Ohtake N, Takei T, Yamanaka H. Trends and characteristics in prostate cancer mortality in Japan. Int J Urol 2000;7:254-257.
6. www.cancer.fi/.
7. Shimizu H, Ross RK, Bernstein L, Yatani R, Henderson BE, Mack TM. Cancers of the prostate and breast among Japanese and white immigrants in Los Angeles country. Br J Cancer 1991;63:963-966.
8. Greenwald P, Lieberman R. Chemoprevention trials for prostate cancer. In: Chung LWK, Issacs WB, Simons JW, editors. Prostate cancer. NJ: Humana Press, Inc.; 2001. pp 499-518.
9. Thompson IM, Goodman PJ, Tangen CM, Lucia MS, Miller GJ, Ford LG, Lieber MM, Cespedes RD, Atkins JN, Lippman SM, Carlin SM, Ryan A, Szczepanek CM, Crowley JJ, Coltman CA Jr. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224.
10. Etminan M, Takkouche B, Caamano-Isorna F. The role of tomato products and lycopene in the prevention of prostate cancer: A meta-analysis of observational studies. Cancer Epidemiol Biomarkers Prev 2004;13:340-345.
11. Lee MM, Gomez SL, Chang JS, Wey M, Wang RT, Hsing AW. Soy and isoflavone consumption in relation to prostate cancer risk in China. Cancer Epidemiol Biomarkers Prev 2003;12:665-668.
12. Brawley OW, Barnes ST. Potential agents for prostate cancer chemoprevention. Epidemiol Rev 2001;23:168-172.
13. Adlercreutz H. Western diet and western diseases: Some hormonal and biochemical mechanisms and associations. Scand J Clin Lab Invest Suppl 1990;201:3-23.
14. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T, Okada H. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am J Clin Nutr 1991;54:1093-1100.
15. Sonoda T, Nagata Y, Mori M, Miyanaga N, Takashima N, Okumura K, Goto K, Naito S, Fujimoto K, Hirao Y, Takahashi A, Tsukamoto T, Fujioka T, Akaza H. A case-control study of diet and prostate cancer in Japan: Possible protective effect of traditional Japanese diet. Cancer Sci 2004;95:238-242.
16. Ozasa K, Nakao M, Watanabe Y, Hayashi K, Miki T, Mikami K, Mori M, Sakauchi F, Washio M, Ito Y, Suzuki K, Wakai K, Tamakoshi A. Serum phytoestrogens and prostate cancer risk in a nested case-control study among Japanese men. Cancer Sci 2004;95:65-71.
17. Adlercreutz H, Markkanen H, Watanabe S. Plasma concentrations of phyto-oestrogens in Japanese men. Lancet 1993;342:1209-1210.
18. Mousavi Y, Adlercreutz H. Genistein is an effective stimulator of sex hormone-binding globulin production in hepatocarcinoma human liver cancer cells and suppresses proliferation of these cells in culture. Steroids 1993;58:301-304.
19. Evans BA, Griffiths K, Morton MS. Inhibition of 5 alpha-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 1995;147:295-302.
20. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, Itoh N, Shibuya M, Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 1987;262:5592-5595.
21. Okura A, Arakawa H, Oka H, Yoshinari T, Monden Y. Effect of genistein on topoisomerase activity and on the growth of [val 12]Ha-Ras-transformed NIH 3T3 cells. Biochem Biophys Res Commun 1988;157:183-189.
22. Makishima M, Honma Y, Hozumi M, Sampi K, Hattori M, Umezawa K, Motoyoshi K. Effects of inhibitors of protein tyrosine kinase activity and/or phosphatidylinositol turnover on differentiation of some human myelomonocytic leukemia cells. Leuk Res 1991;15:701-708.
23. Adlercreutz H, Bannwart C, Wahala K, Makela T, Brunow G, Hase T, Arosernena PJ, Kellis JT Jr, Vickery LE. Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 1993;44:147-153.
24. Fritz WA, Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol Cell Endocrinol 2002;186:89-99.
25. Farhan H, Wahala K, Adlercreutz H, Cross HS. Isoflavonoids inhibit catabolism of vitamin D in prostate cancer cells. J Chromatogr B Analyt Technol Biomed Life Sci 2002;777:261-268.
26. Farhan H, Wahala K, Cross HS. Genistein inhibits vitamin D hydroxylases CYP24 and CYP27B1 expression in prostate cells. J Steroid Biochem Mol Biol 2003;84:423-429.
27. Landstrom M, Zhang JX, Hallmans G, Aman P, Bergh A, Damber JE, Mazur W, Wahala K, Adlercreutz H. Inhibitory effects of soy and rye diets on the development of dunning R3327 prostate adenocarcinoma in rats. Prostate 1998;36:151-161.
28. Jarred RA, Keikha M, Dowling C, McPherson SJ, Clare AM, Husband AJ, Pedersen JS, Frydenberg M, Risbridger GP. Induction of apoptosis in low to moderate-grade human prostate carcinoma by red clover-derived dietary isoflavones. Cancer Epidemiol Biomarkers Prev 2002;11:1689-1696.
29. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, Montesano R, Schweigerer L. Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 1993;90:2690-2694.
30. Setchell KD, Brown NM, Lydeking-Olsen E. The clinical importance of the metabolite equol-A clue to the effectiveness of soy and its isoflavones. J Nutr 2002;132:3577-3584.
31. Wang GJ, Lapcik O, Hampl R, Uehara M, Al-Maharik N, Stumpf K, Mikola H, Wahala K, Adlercreutz H. Time-resolved fluoroimmunoassay of plasma daidzein and genistein. Steroids 2000;65:339-348.
32. Hong SJ, Kim SI, Kwon SM, Lee JR, Chung BC. Comparative study of concentration of isoflavones and lignans in plasma and prostatic tissues of normal control and benign prostatic hyperplasia. Yonsei Med J 2002;43:236-241.
33. Brossner C, Petritsch K, Fink K, Auprich M, Madersbacher S, Adlercrutz H, Rehak P, Petritsch P. Phytoestrogen tissue levels in benign prostatic hyperplasia and prostate cancer and their association with prostatic diseases. Urology 2004;64:707-711.
34. Morton MS, Chan PS, Cheng C, Blacklock N, Matos-Ferreira A, Abranches-Monteiro L, Correia R, Lloyd S, Griffiths K. Lignans and isoflavonoids in plasma and prostatic fluid in men: Samples from Portugal, Hong Kong, and the United Kingdom. Prostate 1997;32:122-128.
35. Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein suppresses chemically induced prostate cancer in lobund-wistar rats. Cancer Lett 2002;186:11-18.
36. Wiseman H, Casey K, Bowety EA, Duffy R, Davies M, Rowland IR, Lloyd AS, Murray A, Thompson R, Clarke DB. Influence of 10 wk of soy consumption on plasma concentrations and excretion of isoflavonoids and on gut microflora metabolism in healthy adults. Am J Clin Nutr 2004;80:692-699.
37. Frankenfeld CL, McTiernan A, Aiello EJ, Thomas WK, LaCroix K, Schramm J, Schwartz SM, Holt VL, Lampe JW. Mammographic density in relation to daidzein-metabolizing phenotypes in overweight, postmenopausal women. Cancer Epidemiol Biomarkers Prev 2004;13:1156-1162.
38. Akaza H, Miyanaga N, Takashima N, Naito S, Hirao Y, Tsukamoto T, Mori M. Is daidzein non-metabolizer a high risk for prostate cancer? A case-controlled study of serum soybean isoflavone concentration. Jpn J Clin Oncol 2002;32:296-300.
39. Watanabe S, Yamaguchi M, Sobue T, Takahashi T, Miura T, Arai Y, Mazur W, Wahala K, Adlercreutz H. Pharmacokinetics of soybean isoflavones in plasma, urine and feces of men after ingestion of 60 g baked soybean powder (Kinako). J Nutr 1998;128:1710-1715.
40. Kuiper GG, Lemmen JG, Carlsson B, Corton JC, Safe SH, van der Saag PT, van der Burg B, Gustafsson JA. Interaction of estrogenic chemicals and phytoestrogens with estrogen receptor beta. Endocrinology 1998;139:4252-4263.